Ron Squarer Insider Profile

4 Followers
Ron Squarer, CEO, Director at Array Biopharma, holds 11.88K shares in Travere Therapeutics (Ticker: TVTX), holds 0.00 shares in Array Biopharma (Ticker: ~ARRY), holds ― shares in Deciphera Pharmaceuticals (Ticker: DCPH).
tipranks
Ron Squarer

Ron Squarer
Array Biopharma (~ARRY)
CEO, Director

Ranked #21,852 out of 78,624 Corporate Insiders

Profitable Transactions

100%
2 out of 2 Profitable Transactions

Average Return

+74.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$282K
100.00%
0.00%
A breakdown of Ron Squarer's holdings

Insider Roles

Travere Therapeutics
(TVTX)
Director
Deciphera Pharmaceuticals
(DCPH)
Director
Roles that Ron Squarer holds in companies

Most Profitable Insider Trade

Stock:
Hospira Inc
(HSP)
Rating:Informative Buy
Date:Feb 26, 2009 - Feb 26, 2010
Return:+117.90%
The most profitable trade made by Ron Squarer

Ron Squarer's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
~ARRY
Array Biopharma
Jul 30, 2019
Uninformative Sell
12.47M
$0.00
Travere Therapeutics
May 19, 2020
Director
Uninformative Buy
$282.27K
Deciphera Pharmaceuticals
Director
HSP
Hospira Inc
Feb 28, 2011
Uninformative Buy
$0.00
List of latest transactions for each holding click on a transaction to see Ron Squarer's performance on stock

Ron Squarer insider profile FAQ

What is the percentage of profitable transactions made by Ron Squarer?
The percentage of profitable transactions made by Ron Squarer is 100%.
    What is the average return per transaction made by Ron Squarer?
    The average return per transaction made by Ron Squarer is 74.40%.
      What stocks does Ron Squarer hold?
      Ron Squarer holds: ~ARRY, TVTX, DCPH, HSP stocks.
        What was Ron Squarer’s latest transaction?
        Ron Squarer latest transaction was an Uninformative Buy of ―.
          What was Ron Squarer's most profitable transaction?
          Ron Squarer’s most profitable transaction was an Informative Buy of HSP stock on February 26, 2009. The return on the trade was 117.90%.
            What is Ron Squarer's role in Array Biopharma?
            Ron Squarer's role in Array Biopharma is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.